Cover Image
市場調查報告書

生技仿製藥單株抗體 (MAb)全球市場預測 2016-2026年:Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab與Abciximab

Biosimilar Monoclonal Antibodies Market Forecast 2016-2026: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

出版商 Visiongain Ltd 商品編碼 275993
出版日期 內容資訊 英文 203 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生技仿製藥單株抗體 (MAb)全球市場預測 2016-2026年:Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab與Abciximab Biosimilar Monoclonal Antibodies Market Forecast 2016-2026: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab
出版日期: 2016年02月25日 內容資訊: 英文 203 Pages
簡介

本報告針對世界生技仿製藥單株抗體 (MAb) 市場進行調查、提供市場預測、2次市場分類收益預測、上市、開發中生技仿製藥抗體分類收益預測、主要國家市場分析與預測、STEP分析與主要企業檔案。

第1章 報告概要

第2章 介紹:生技仿製藥單株抗體

  • 自然抗體:免疫系統關鍵
  • 從血清療法到單株抗體 (MAbs)
  • MAb人體化
  • 生技藥品和生技仿製藥
  • 生技仿製藥需求的理由?
  • 生技仿製藥開發檢討事項
  • 已經上市的生技仿製藥單株抗體

第3章 生技仿製藥單株抗體世界市場預測

  • 現在世界生技仿製藥單株抗體市場
  • 世界生技仿製藥MAb市場:收益預測
  • 世界生技仿製藥MAb市場□化合物分類:收益、市場佔有率預測
  • 世界生技仿製藥MAb市場□化合物分類:收益預測
  • 生技仿製藥MAb市場成長促進因素、阻礙因素
  • 阻礙生技仿製藥MAb市場成長的原因?
第4章 各生技仿製藥MAb製品:上市藥、臨床藥
  • 上市生技仿製藥
  • 臨床生技仿製藥

第5章 主要國家生技仿製藥單株抗體市場

  • 主要國家市場生技仿製藥MAb狀況
  • 主要國家市場佔有率預測期間變化?
  • 印度:目前的生技仿製藥MAb冠軍但預計成長將減緩
  • 俄羅斯:缺乏規範但短期順利
  • 韓國:市場受到早期生技仿製藥規章的好處
  • 中國:片段的生技仿製藥MAb市場
  • 巴西:ANVISA生技仿製藥規範與EMA類似
  • EU生技仿製藥MAb展望
  • 日本生技仿製藥MAb展望
  • 美國生技仿製藥MAb展望

第6章 主要企業

  • 生技仿製藥MAb開發合作
  • BioXpress:以專利到期為目標
  • Celltrion:企業市場規模急速擴大至107億美元以上
  • Harvest Moon:6項化合物開發中
  • Genor Biopharma:中國生技仿製藥是MAb市場領導
  • Samsung Bioepsis
  • Mabion:波蘭主要生技仿製藥MAb開發企業
  • Gene Techno Science:持續收益擴大
  • 印度Biocon
  • Coherus Biosciences
  • BIOCAD:生技仿製藥 Rituximab販售世界居冠
  • 大型企業與生技仿製藥MAb市場
  • 生技仿製藥MAb市場矚目的收購

第7章 生技仿製藥單株抗體市場定性分析

  • 強弱點
  • 機會與威脅
  • 生技仿製藥MAb市場影響於社會、技術、經濟與政治因素 (STEP分析)

第8章 調查問卷

第9章 結論

  • 生技仿製藥單株抗體:世界市場
  • 市場、臨床化合物的未來
  • 主要國家市場
  • 主要企業
  • 產業動向現狀、預測

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0092

You need a single report that pulls together best practice, forecasts, primary research and sales figures of biosimilar monoclonal antibodies all in one place. This report provides you with that vital information and it does it, today.

Our new report discusses issues and events affecting the biosimilar monoclonal antibody market.

You will find discussions, including qualitative analyses on:

  • Patent expiries and how they will affect the market
  • Newly published guidelines on biosimilarity by the Chinese FDA and the US FDA
  • The challenges facing the market, including the complexity of the molecules and the use of biobetters
  • How demand in emerging markets for cheap drugs will fuel demand
  • How clinician and patient confidence in biosimilar monoclonal antibodies will affect the rate of adoption

image1

Convergence and co-ordination of regulatory guidelines between national markets will help to clarify what manufacturers need to do in order to get their products released across multiple market places. Unified global guidelines will also help to prevent market fragmentation, as is the case at present in India. Many biosimilar mAbs have been released here as the regulatory guidelines are not as stringent as those in more developed markets. Demand will be fuelled by the need for cheaper drugs as healthcare budgets become increasingly strained by growing populations, and ageing demographics associated with a greater prevalence of cancer amongst other indications.

Our 203 page report provides 72 tables and 72 figures covering 6 leading submarkets and 13 national markets. Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, interviews, trends, opportunities, and revenue predictions. Increasing development and use of biosimilar monoclonal antibodies will increase worldwide sales of such products from 2016 to 2026, our study shows.

image2

Read the full transcript of 2 exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:

  • Dr Seoyoung Kim, Assistant Professor of Medicine at Harvard Medical School and Associate Physician, Brigham and Women's Hospital
  • Professor Steve Morgan, expert in pharmaceutical policy and Professor of health policy in the School of Population and Public Health, University of British Columbia

Who should read this report: directors of:

  • Biosimilars
  • Biosimilar monoclonal antibodies
  • Monoclonal antibodies
  • Regulatory bodies
  • Biobetters
  • CMOs

image3

What are the prospects in the leading regions and countries?

In our study you will find individual revenue forecasts to 2026 for the leading regional and national markets:

  • US
  • Japan
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • China
  • India
  • Brazil
  • Russia
  • South Korea
  • Rest of the World

Why you must buy this totally independent report:

This report features news, insights, the latest developments and an in depth survey of the biosimilar monoclonal antibody market with up-to-date analysis as well as tables, graphs and charts. This report is a vital addition to gaining an understanding of this market sector and will give your company 'the edge' on your competitors. You cannot afford to be without this latest report from visiongain.

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Find in this report:

  • Forecast from 2016 - 2026 of the six segments of the market by compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab and Bevacizumab.
  • Forecast from 2016 - 2026 of the 17 biosimilar mAbs in the market.
  • Profiles of 10 leading companies either with biosimilar mAbs already on the market or in the pipeline in addition to new merger and acquisition analysis.

Table of Contents

1. Report Overview

  • 1.1 Overview of Biosimilar Monoclonal Antibodies: R&D, Industry and Market
  • 1.2 Why You Should Read this Report
  • 1.3 How This Study Delivers
  • 1.4 Main Questions Answered by the Analysis
  • 1.5 Who is This Investigation For?
  • 1.6 Method of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Associate visiongain Reports
  • 1.9 About visiongain

2. Introduction to Biosimilar Monoclonal Antibodies

  • 2.1 Natural Antibodies: Key to the Immune System
  • 2.2 From Serum therapy to Monoclonal Antibodies
  • 2.3 Humanising the mAb
  • 2.4 Biologics (Biological Drugs) and Biosimilars
  • 2.5 Why are Biosimilars in High Demand?
  • 2.6 Considerations for the Development of Biosimilars
    • 2.6.1 Biologics and Biosimilars Are Large, Complex Molecules
    • 2.6.2 How Much of a Concern is Immunogenicity?
  • 2.7 Biosimilar Monoclonal Antibodies Currently on the Market

3. The Global Market for Biosimilar Monoclonal Antibodies, 2016-2026

  • 3.1 The Present Global Market for Biosimilar Monoclonal Antibodies
  • 3.2 The Global Market for Biosimilar mAbs: A Revenue Forecast, 2016-2026
  • 3.3 The Global Market for Biosimilar mAbs by Compound: Predictions for Revenue and Market Share in 2020 and 2026
  • 3.4 The World Market for Biosimilar mAbs by Compound: Revenue Forecasts, 2016-2026
    • 3.4.1 Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
    • 3.4.2 Biosimilar Infliximab: Currently the Second Largest Submarket
      • 3.4.2.1 Biosimilar Infliximab Revenue Forecast 2016-2026
    • 3.4.3 Biosimilar Rituximab: The current Leading Submarket Driven by Sales in Russia
      • 3.4.3.1 Biosimilar Rituximab: Revenue Forecast 2016-2026
    • 3.4.4 Biosimilar Abciximab: Revenue Forecast 2016-2026
      • 3.4.4.1 Biosimilar Abciximab: Revenue Forecast, 2016-2026
    • 3.4.5 Biosimilar Trastuzumab: Pipeline Rich in Phase III Candidates
      • 3.4.5.1 Biosimilar Trastuzumab: Revenue Forecast, 2016-2026
    • 3.4.6 Biosimilar Adalimumab: Patents Hold Back Revenue on a Large Pipeline
      • 3.4.6.1 Biosimilar Adalimumab: Revenue Forecast 2016-2026
    • 3.4.7 Biosimilar Bevacizumab: Will Late Entry to the Biosimilar mAb Market Restrict Revenue?
      • 3.4.7.1 Biosimilar Bevacizumab: Revenue Forecast, 2016-2026
  • 3.5 Drivers and Restraints for the Biosimilar mAb market 2016-2026
    • 3.5.1 Driving Factors of the Biosimilar mAb Market 2016-2026
  • 3.6 Restraining Factors of the Biosimilar mAb Market 2016-2026

4. Individual Biosimilar mAb Products: Marketed and Pipeline Drugs, 2016-2026

  • 4.1 Biosimilar mAbs on the Market in 2015
    • 4.1.1 Celltrion's Remsima/ Hospira's Inflectra. Egis' Flammegis (Infliximab): The First Official Biosimilar Monoclonal Antibody
      • 4.1.1.1 Remsima/Inflectra/Flammegis Revenue Forecast, 2016-2026
    • 4.1.2 Infimab (Infliximab): Launched a Quarter Ahead of Schedule
      • 4.1.2.1 Infimab Revenue Forecast ($m) 2016-2026
      • 4.1.2.2 Dr Reddy's Reditux (Rituximab): No Application for EU or US Approval
      • 4.1.2.3 Reditux Revenue Forecast, 2016-2026
    • 4.1.3 Intas Pharmaceuticals' Mabtas (Rituximab)
      • 4.1.3.1 Mabtas (Rituximab) Revenue Forecast 2016-2026
    • 4.1.4 AcellBia (Rituximab): Sales in Russia Generating Large Revenue Figures
      • 4.1.4.1 AcellBia Revenue Forecast 2016-2026
    • 4.1.5 MABALL: Faces Competition from other Biosimilar Rituximabs in India
      • 4.1.5.1 MABALL Revenue Forecast, 2016-2026
    • 4.1.6 Isu Abxis' Clotinab (abciximab):
      • 4.1.6.1 Clotinab Revenue Forecast, 2016-2026
    • 4.1.7 AbcixiRel: The First Indian Abciximab Biosimilar
      • 4.1.7.1 AbcixiRel Revenue Forecast 2016-2026
    • 4.1.8 Herzuma (Trastuzumab): Approved in South Korea
      • 4.1.8.1 Herzuma Revenue Forecast 2016-2026
    • 4.1.9 CANMAb/Hertraz (Trastuzumab)
      • 4.1.9.1 CANMAb/Hertraz Revenue Forecast, 2016-2026
  • 4.2 Pipeline Biosimilars
    • 4.2.1 BI695500 (Rituximab): An EU Launch Anticipated in 2017
      • 4.2.1.1 BI695500 Revenue Forecast, 2016-2026
    • 4.2.2 CT-P10 (Rituximab): Celltrion's Reputation for Biosimilars will Assist Sales
      • 4.2.2.1 Celltrion's CT-P10 (Rituximab) Revenue Forecast, 2016-2026
    • 4.2.3 Boehringer Ingelheim's BI695501 (Adalimumab)
      • 4.2.3.1 BI695501 Revenue Forecast, 2016-2026
    • 4.2.4 BCD-022 (Trastuzumab): Currently under Development in Russia Only
      • 4.2.4.1 BCD-022 Revenue Forecast, 2016-2026
    • 4.2.5 Fujifilm Kyowa Kirin Biologics' FKB327 (Adalimumab)
      • 4.2.5.1 FKB327 Revenue Forecast, 2016-2026
    • 4.2.6 Fujifilm Kyowa Kirin Biologics' FKB238 (Bevacizumab)
      • 4.2.6.1 Fujifilm Kyowa Kirin Biologics' FKB238 Revenue Forecast 2016-2026
    • 4.2.7 BCD-021 (Bevacizumab): Russia Will Contribute the Most Revenue
      • 4.2.7.1 BCD-021 Revenue Forecast 2016-2026

5. Leading National Markets for Biosimilar Monoclonal Antibodies

  • 5.1 What Were the Leading National Markets for Biosimilar mAbs in 2015?
  • 5.2 How Will National Market Shares Change Over the Forecast Period?
  • 5.3 India: The Current Leading Nation for Biosimilar mAbs but Growth will Slow
    • 5.3.1 India Releases New Biosimilar Development Guidelines
    • 5.3.2 Indian Biosimilar Submarket Forecast 2016-2026
  • 5.4 Russia: Lack of Regulatory Framework Works Well in the Short Term
    • 5.4.1 Russian Government Backed 'Pharma 2020' Initiative
    • 5.4.2 Russian Biosimilar mAb Revenue Forecast, 2016-2026
  • 5.4 South Korean Market has Benefitted from Early Biosimilar Guidelines
    • 5.4.1 Significant Investment in Biosimilars in South Korea
    • 5.4.2 South Korean Biosimilar mAb Revenue Forecast, 2016-2026
  • 5.5 China: A Fragmented Biosimilar mAb Market
    • 5.5.1 Chinese FDA Publishes Finalised Biosimilar Guidelines in 2015
    • 5.5.2 China Biosimilar mAb Revenue Forecast, 2016-2026
  • 5.6 Brazil: ANVISA's Biosimilar Regulations Are Similar the EMA's
    • 5.6.1 Brazil Biosimilar mAb Revenue Forecast 2016-2026
  • 5.7 The Outlook for Biosimilar mAbs in the EU 2016-2026
    • 5.7.1 Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar mAbs
    • 5.7.2 Biosimilar mAbs in the EU5: Revenue Forecasts, 2016-2026
    • 5.7.3 Germany: the Current EU Leader
    • 5.7.4 France: Will the Uptake of Biosimilar mAbs be Restricted?
    • 5.7.5 UK: NICE Recommends Use of Remsima for Certain Indications
    • 5.7.6 Italy: Healthcare Spending Cuts Will Drive Growth
    • 5.7.7 Spain: High Biosimilar mAb Discounts Expected
  • 5.8 The Outlook for Biosimilar mAbs in Japan
    • 5.8.1 Regulations for Naming Biosimilars
    • 5.8.2 Biosimilar mAb Market Activity in Japan
    • 5.8.3 Japanese Biosimilar Submarket Forecast 2016-2026
  • 5.9 US Biosimilar mAb Outlook: None Currently on the Market
    • 5.9.1 US FDA Biosimilar Guidelines were Released in 2015
    • 5.9.2 Legal Challenges for Biosimilars in the US
    • 5.9.3 State Regulation of Biosimilar Substitution
    • 5.9.4 The US Biosimilar mAb Market Revenue Forecast, 2016-2026

6. Leading Companies in Biosimilar Monoclonal Antibodies

  • 6.1 Collaboration in Biosimilar mAb Development
  • 6.2 BioXpress: Targeting Patent Expiry Dates in 2019-2023
  • 6.3 Celltrion: Company's Market Value Surges to Exceed $10.7bn
  • 6.4 Harvest Moon: Six Compounds Under Development
  • 6.5 Genor Biopharma: A Biosimilar mAb Market Leader in China
  • 6.6 Samsung Bioepsis
  • 6.7 Mabion: Poland's Leading Biosimilar mAb Developer
  • 6.8 Gene Techno Science: Substantial Revenue Increases Since 2014
  • 6.9 India's Biocon:
  • 6.10 Coherus Biosciences
  • 6.11 BIOCAD: World Leader Biosimilar Rituximab Sales
  • 6.12 Big Pharma and the Biosimilar mAb Market
  • 6.13 Significant Acquisitions in the Biosimilar mAb Market
    • 6.13.1 Pfizer Acquires Hospira
    • 6.13.2 Epirus Acquires Bioceros

7. Qualitative Analysis of Biosimilar Monoclonal Antibodies

  • 7.1 Strengths and Weaknesses of the Biosimilar Monoclonal Antibody Market, 2016-2026
    • 7.1.1 Global Demand for Affordable Biopharmaceuticals has Never Been Greater
    • 7.1.2 Adoption of Biosimilar mAbs will be Proportional to the Rate of Discount
    • 7.1.3 Approval Pathways are Now Established in Developed Markets
    • 7.1.4 Complexity of Protein Molecules Leads to Technical Challenges
    • 7.1.5 Doctor and Patient Confidence May Take Time
  • 7.2 Opportunities and Threat Facing the Biosimilar Monoclonal Antibody Market, 2016-2026
    • 7.2.1 Market Opportunities from Patent Expiries and a Well-stocked Pipeline
    • 7.2.2 Substitution may Not Occur Automatically
    • 7.2.3 Biobetters Offer a Serious Threat to the Production and Uptake of Biosimilars
  • 7.3 Social and Technological Forces Influencing the Biosimilar Monoclonal Antibodies Market 2016-2026
    • 7.3.1 Social Factors: Driving or Restraining the Market?
    • 7.3.2 Technological Factors Concentrate on Reducing Costs and Increasing Ease of Production
    • 7.3.3 Economic Pressures Raise Demand for Biosimilar mAbs
      • 7.3.3.1 Fragmentation of the Market Could Limit Individual Drug Revenues
    • 7.3.4 Political Issues: Stringent Regulations Hurdles to Market Entry

8. Research Interviews

  • 8.1 Interview with Professor Steve Morgan, UBC
    • 8.1.1 On the Benefits of mAbs
    • 8.1.2 On the FDA Biosimilar Regulatory Pathway
    • 8.1.3 On the Challenges in Bringing Biosimilar mAbs to Market
    • 8.1.4 On the Rate of Uptake of Biosimilar mAbs
    • 8.1.5 On What Can be Learnt From Previous Case Studies
  • 8.2 Interview with Dr. Seoyoung C. Kim, Harvard
    • 8.2.1 On the use of Remsima in Korea
    • 8.2.2 On Adoption Rates of Biosimilar Infliximab in the US
    • 8.2.3 On the Indications for Biosimilar Infliximab

9. Conclusions From our Study

  • 9.1 Biosimilar Monoclonal Antibodies: World Market, 2016-2026
  • 9.2 Future of Compounds on the Market and in the Pipeline
  • 9.3 Leading National Markets for Biosimilar Monoclonal Antibodies 2016-2026
  • 9.4 Leading Companies in the Biosimilar mAb Market
  • 9.5 Current and Expected Industry Trends 2016-2026
    • 9.5.1 Cost Control of Healthcare Will Work in Favour mAbs
    • 9.5.2 Upcoming Patent Expiries in Developed Markets Offer Large Market Potential
    • 9.5.3 Complex Production Processes are a Restraining Factor
    • 9.5.4 Clinician and Patient Confidence Must be Maximised to Ensure Uptake
    • 9.5.5 Biobetters Pose a Threat

Visiongain Report Sales Order Form

  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 1.1 Biosimilar mAbs: Global Revenue Forecast by Reference Compound 2016-2026
  • Table 2.1 Classification of Monoclonal Antibodies
  • Table 2.2 Murine Monoclonal Antibodies on the Market, 2016
  • Table 2.3 Chimeric Monoclonal Antibodies on the Market, 2016
  • Table 2.4 Humanised Monoclonal Antibodies on the Market, 2016
  • Table 2.5 Fully Human Monoclonal Antibodies on the Market, 2016
  • Table 2.6 Revenue of Originator Monoclonal Antibody Products in 2014
  • Table 3.1 Biosimilar mAb Global Market: Revenue Forecast ($m), 2016-2026
  • Table 3.2 Global Market for Biosimilar mAbs: Revenues ($m) and Market Shares (%) by Reference Compound, 2015, 2020 and 2026
  • Table 3.3 EU and US Patent Expiry Dates for the Main mAb Reference Products
  • Table 3.4 Biosimilar mAbs: Global Revenue Forecast by Reference Compound 2016-2026
  • Table 3.5 Biosimilar Infliximab: Compounds Awaiting Approval in the Pipeline
  • Table 3.6 Biosimilar Infliximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2026
  • Table 3.7 Biosimilar Rituximab: Compounds Marketed and in the Pipeline, 2016
  • Table 3.8 Biosimilar Rituximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2026
  • Table 3.9 Biosimilar Abciximab: Compounds Marketed and in the Pipeline, 2016
  • Table 3.10 Biosimilar Abciximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2026
  • Table 3.11 Biosimilar Trastuzumab: Compounds Marketed and in the Pipeline, 2016
  • Table 3.12 Biosimilar Trastuzumab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2026
  • Table 3.13 Biosimilar Adalimumab: Compounds Marketed and in the Pipeline, 2016
  • Table 3.14 Biosimilar Adalimumab: Global Revenue Forecast 2016-2026
  • Table 3.15 Biosimilar Bevacizumab: Compounds Marketed and in the Pipeline, 2016
  • Table 3.16 Biosimilar Bevacizumab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2026
  • Table 4.1 Biosimilar mAbs on the Market in 2015: Revenues ($m) and Market Shares (%)
  • Table 4.2 Remsima/Inflectra/Flammegis (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.3 Infimab (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.4 Reditux (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.5 Mabtas (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.6 Biocad Distribution Partners for AcellBia, 2016
  • Table 4.7 AcellBia (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.8 MABALL (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.9 Clotinab (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.10 AbcixiRel (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.11 Herzuma (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.12 CANMAb/Hertraz (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.13 BI695500 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.14 CT-P10 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.15 BI695501 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.16 BCD-022 (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.17 FKB327 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.18 FKB238 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 4.19 BCD-021 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
  • Table 5.1 Leading National Markets for the Global Biosimilar mAb Industry, 2015
  • Table 5.2 Leading National Markets for the Global Biosimilar mAb Industry, 2016-2026
  • Table 5.3 The Indian Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
  • Table 5.4 The Russian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
  • Table 5.5 The South Korean Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
  • Table 5.6 The Chinese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
  • Table 5.7 The Brazilian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
  • Table 5.8 The EU5 Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
  • Table 5.9 The German Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
  • Table 5.10 The French Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
  • Table 5.11 The UK Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
  • Table 5.12 The Italian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
  • Table 5.13 The Spanish Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
  • Table 5.14 The Japanese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
  • Table 5.15 Finalised FDA Biosimilar Guidelines, 2015
  • Table 5.16 The US Biosimilar mAb Market: Revenue ($m) and Annual Growth (%) Forecast, 2016-2026
  • Table 6.1 Companies in the Biosimilar mAb Industry by Number of Compounds in Development, 2016
  • Table 6.2 Selected Collaborations for Biosimilar mAb Development, 2009-2015
  • Table 6.3 BioXpress: Compounds in the Pipeline, 2016
  • Table 6.4 Tests Carried Out By BioXpress During Biosimilar mAb Development, with Objectives
  • Table 6.5 Compounds in Celltrion's Pipeline: Compound Name, Generic Name, Development Stage and Anticipated Year of Approval, 2016
  • Table 6.6 Genor Biopharma: Biosimilar mAbs Pipeline, 2016
  • Table 6.7 Mabion: Compounds in the Pipeline and Their Development Stage, 2016
  • Table 6.8 Gene Techno Science: Revenue ($m), from 2013-2015
  • Table 6.9 Biocon: Compounds in the Pipeline and Their Stage of Development, 2016
  • Table 6.10 Big Pharma's Positions in the Biosimilar mAb Industry, 2016
  • Table 6.11 Significant Acquisitions in the Biosimialr mAb Market 2015
  • Table 7.1 Strengths and Weaknesses of the Biosimilar mAb Market, 2016-2026
  • Table 7.2 Opportunities and Threats Facing the Biosimilar mAb Market, 2016-2026
  • Table 7.3 Social and Technological Factors Influencing the Biosimilar mAb Market, 2016-2026

List of Figures

  • Figure 1.1 Main Compound Classes of Biosimilar mAbs, 2016
  • Figure 2.1 Structure of an Antibody
  • Figure 3.1 Global Market for Biosimilar mAbs: Revenue forecast ($m), 2016-2026
  • Figure 3.2 The Biosimilar mAb Market: Market Share (%) by compound in 2015
  • Figure 3.3 The Biosimilar mAb Market: Market Share (%) by compound in 2020
  • Figure 3.4 The Biosimilar mAb Market: Market Share (%) by compound in 2026
  • Figure 3.5 Biosimilar Infliximab: Global Revenue ($m) Forecast 2016-2026
  • Figure 3.6 Biosimilar Rituximab: Global Revenue ($m) Forecast 2016-2026
  • Figure 3.7 Biosimilar Abciximab: Global Revenue ($m) Forecast 2016-2026
  • Figure 3.8 Biosimilar Trastuzumab: Global Revenue ($m) Forecast 2016-2026
  • Figure 3.9 Biosimilar Adalimumab: Global Revenue ($m) Forecast 2016-2026
  • Figure 3.10 Biosimilar Bevacizumab: Global Revenue ($m) Forecast 2016-2026
  • Figure 3.11 Drivers and Restraints for the Global Biosimilar mAb market 2016-2026
  • Figure 4.1 Biosimilar mAb Versions on the Market: Market Share (%) 2015
  • Figure 4.2 Biosimilar mAb Versions on the Market: Market Share (%) 2020
  • Figure 4.3 Biosimilar mAb Versions on the Market: Market Share (%) 2026
  • Figure 4.4 Remsima/Inflectra/Flammegis (Infliximab): Revenue Forecast ($m), 2016-2026
  • Figure 4.5 Remsima/Inflectra/Flammegis (Infliximab): AGR Forecast (%), 2016-2026
  • Figure 4.6 Infimab (Infliximab): Revenue Forecast ($m) 2016-2026
  • Figure 4.7 Infimab (Infliximab): AGR Forecast (%) 2016-2026
  • Figure 4.8 Reditux (Rituximab): Revenue Forecast ($m) 2016-2026
  • Figure 4.9 Reditux (Rituximab): AGR Forecast (%) 2016-2026
  • Figure 4.10 Mabtas (Rituximab): Revenue Forecast ($m) 2016-2026
  • Figure 4.11 Mabtas (Rituximab): AGR Forecast (%) 2016-2026
  • Figure 4.12 AcellBia (Rituximab): Revenue Forecast ($m) 2016-2026
  • Figure 4.13 AcellBia (Rituximab): AGR Forecast(%) 2016-2026
  • Figure 4.14 MABALL (Rituximab): Revenue Forecast ($m) 2016-2026
  • Figure 4.15 MABALL (Rituximab): AGR Forecast(%) 2016-2026
  • Figure 4.16 Clotinab (Abciximab): Revenue Forecast ($m) 2016-2026
  • Figure 4.17 Clotinab (Abciximab): AGR Forecast (%) 2016-2026
  • Figure 4.18 AbcixiRel (Abciximab): Revenue Forecast ($m) 2016-2026
  • Figure 4.19 AbcixiRel (Abciximab): AGR Forecast (%) 2016-2026
  • Figure 4.20 Herzuma (Trastuzumab): Revenue Forecast ($m) 2016-2026
  • Figure 4.21 Herzuma (Trastuzumab): AGR Forecast (%) 2016-2026
  • Figure 4.22 CANMAb/Hertraz (Trastuzumab): Revenue Forecast ($m) 2016-2026
  • Figure 4.23 CANMAb/Hertraz (Trastuzumab): AGR Forecast (%) 2016-2026
  • Figure 4.24 BI695500 (Rituximab): Revenue Forecast ($m) 2016-2026
  • Figure 4.25 BI695500 (Rituximab): AGR Forecast (%) 2018-2026
  • Figure 4.26 CT-P10 (Rituximab): Revenue Forecast ($m) 2016-2026
  • Figure 4.27 CT-P10 (Rituximab): AGR Forecast (%) 2019-2026
  • Figure 4.28 BI695501 (Adalimumab): Revenue Forecast ($m) 2016-2026
  • Figure 4.29 BI695501 (Adalimumab): AGR Forecast (%)2018-2026
  • Figure 4.30 BCD-022 (Trastuzumab): Revenue Forecast ($m) 2016-2026
  • Figure 4.31 BCD-022 (Trastuzumab): AGR Forecast (%) 2017-2026
  • Figure 4.32 FKB327 (Adalimumab): Revenue Forecast ($m) 2016-2026
  • Figure 4.33 FKB327 (Adalimumab): AGR Forecast (%) 2018-2026
  • Figure 4.34 FKB238 (Adalimumab): Revenue Forecast ($m) 2016-2026
  • Figure 4.35 FKB238 (Adalimumab): AGR Forecast(%) 2021-2026
  • Figure 4.36 BCD-021 (Bevacizumab): Revenue Forecast ($m) 2016-2026
  • Figure 4.37 BCD-021 (Bevacizumab): AGR Forecast (%) 2018-2026
  • Figure 5.1 The Biosimilar MAb Market by Country: Market Shares (%) of Revenue, 2015
  • Figure 5.2 The Biosimilar MAb Market: National Submarket Shares (%), 2020
  • Figure 5.3 The Biosimilar MAb Market: National Submarket Shares (%), 2026
  • Figure 5.4 The Indian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
  • Figure 5.5 The Russian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
  • Figure 5.6 The South Korean Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
  • Figure 5.7 The Chinese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
  • Figure 5.8 The Brazilian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
  • Figure 5.9 The EU5 Biosimilar mAb Market: Grouped Revenue Forecast ($m), 2016-2026
  • Figure 5.10 The EU5 Biosimilar mAb Market: Revenue Forecasts ($m) by Country, 2016-2026
  • Figure 5.11 The German Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
  • Figure 5.12 The French Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
  • Figure 5.13 The UK Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
  • Figure 5.14 The Italian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
  • Figure 5.15 The Spanish Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
  • Figure 5.16 The Japanese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
  • Figure 5.17 Biosimilar mAbs in the US: Revenue Forecast ($m), 2016-2026
  • Figure 6.1 Prominent Companies in the Biosimilar mAb Industry: Share (%) of the Pipeline,
  • Figure 9.1 Prominent Compounds in the Biosimilar mAb Market: Comparison of Revenues ($m), 2015, 2020 and 2026
  • Figure 9.2 Forecasted Biosimilar mAbs: Comparison of Revenues ($m), 2015, 2020 and 2026
  • Figure 9.3 Leading National Markets: Revenues ($m), 2015, 2020 and 2026
  • Figure 9.4 Prominent Companies in the Biosimilar mAb Industry: Number of Products in Current Development or in the Pipeline, 2016

Companies Listed

  • Abbott Laboratories
  • AbbVie
  • Aché
  • Actavis
  • AET BioTech
  • Agence française de sécurité sanitaire des produits de santé (ANSM)
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Alexion Pharmaceuticals
  • Alvogen
  • Alvotech
  • Amgen
  • Aprogen
  • Array Bridge
  • AstraZeneca
  • Australia's Pharmaceutical Benefits Advisory Committee
  • Bayer
  • Binex
  • BIO
  • BIOCAD
  • Biocerus
  • Biocon
  • Biogen Idec
  • Bio-Manguinhos
  • Bionovis
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cell Therapeutics
  • Celltrion
  • Celon Pharma £omianki
  • Chinese Centre for Drug Evaluation (CDE)
  • CinnaGen
  • Coherus BioSciences
  • Cour des Comptes (France)
  • Daiichi Sankyo
  • Dong-A
  • Dr. Reddy's Laboratories
  • Egis Pharmaceuticals
  • Eli Lilly
  • Emcure
  • EMS
  • Epirus Biopharmaceuticals
  • European Medicines Agency (EMA)
  • Farmasa
  • Food and Drug Administration (US FDA)
  • Fraunhofer Center for Molecular Biology
  • Fresenius
  • Fujifilm Kyowa Kirin Biologics
  • Gedeon Richter
  • Gene Techno Science
  • Genentech
  • Generics and Biosimilars Initiative
  • Genexo
  • Genor Biopharma
  • GlaxoSmithKline (GSK)
  • Glycotope
  • Hanwha Chemical
  • Harvest Moon
  • Health Canada
  • Hospira
  • Hypermarcas
  • iBio
  • IBSS Biomed
  • ImClone LLC
  • India Brand Equity Foundation
  • Instas Pharmaceuticals
  • Instituto Vital Brazil
  • IPCA Labs
  • Isu Abxis
  • Janssen
  • Johnson & Johnson
  • Korean Food and Drug Administration (KFDA)
  • Kyowa Hakko Kirin
  • Laboratorios Liomont
  • LG Life Sciences
  • London Medicines Evaluation Network Review
  • Lonza
  • Mabion
  • mAbxience
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • MedImmune
  • Merck & Co.
  • Merck Serono
  • Millhouse LLC
  • Ministry of Food and Drug Safety (South Korea)
  • Ministry of Health (Russia)
  • Ministry of Health, Labour and Welfare (MHLW)
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Mustafa Nevzat Pharmaceuticals
  • Mylan
  • Natco Pharma
  • National Institute for Health and Care Excellence (NICE)
  • National Institute for Health Research Horizon Scanning Centre
  • Nichi-Iko Pharmaceutical Co.
  • Nippon Kayaku
  • Norwegian Medical Agency
  • Novartis
  • Oncobiologics
  • Otsuka Pharmaceutical
  • Parexel
  • Patent Trial and Appeal Board
  • Pfizer
  • Pharma Benefits Scheme
  • PharmaPraxis
  • Pharmstandard
  • PhRMA
  • PlantForm
  • Polfarmex
  • Probiomed
  • QuantiaMD
  • Quintiles
  • Reliance Life Sciences
  • Roche
  • Russian Ministry of Health
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Schnell
  • Scientific Centre for Expertise of Medicinal Application Products (Russia)
  • Seattle Genetics
  • Shanghai CP Guojian
  • Shionogi
  • Sorrento
  • Spanish Ministry of Health
  • Spectrum Pharmaceuticals
  • Stada
  • State Food and Drug Administration (SFDA)
  • Synthon
  • Takeda
  • Teva Pharmaceutical Industries
  • The Cancer Centre Bahamas
  • UCB
  • União Química
  • Viropro
  • Walvax Biotechnology
  • Washington Legal Foundation
  • World Health Organization (WHO)
  • Wyeth
  • Zenotech
  • Zhejiang Huahai Pharmaceutical
Back to Top